Recombinant CTLA4 antibody

Catalog No. ABIN7540550

Supplier Product No.: 400-001-mt1

This Humanized Monoclonal antibody specifically detects CTLA4 in FACS, WB and ELISA. It exhibits reactivity toward Human.

Quick Overview for Recombinant CTLA4 antibody (ABIN7540550)

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Antibody Type: Recombinant Antibody

Fragment: Fab fragment

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CTLA4 antibody is un-conjugated

Application: Flow Cytometry (FACS), Western Blotting (WB), ELISA

Clone: Abz521

Product Details anti-CTLA4 Antibody

Supplier Product No.: 400-001-mt1

Supplier: Rockland

Purpose: Recombinant Anti-CTLA4 Fab Antibody

Cross-Reactivity (Details): The purity was estimated to be >95 % by SDS-PAGE analysis.

Purification: Humanized Recombinant CLTA4 Fab fragment was expressed in CHO cells.

Sterility: Sterile filtered

Isotype: IgG1

Application Details

Application Notes:

ELISA_Dilution: User Optimized

Flow_Cytometry_Dilution: User Optimized

Western_Blot_Dilution: User Optimized

Comment:

Humanized Recombinant Anti-CTLA-4 Fab fragment Antibody is tested for use in Flow Cytometry, Western Blot, and ELISA. This antibody recognizes structured CTLA-4 and will work in western blot when the protein has not been denatured with DTT or bMe. Although not tested, this antibody could be useful in in IHC and in in-vivo and other cellular assays. Specific conditions for reactivity should be optimized by the end user.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer:

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Stabilizer: 30 % Glycerol

Preservative: None

Preservative: Without preservative

Storage: 4 °C

Storage Comment: Store vial at 2-8° C. Dilute only prior to immediate use.

Expiry Date: 6 months

Target Details for CTLA4

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Alternative Name: CTLA4

Background: Cytotoxic T-Lymphocyte Associated Protein 4, Ipilimumab, Yervoy, recombinant Monoclonal CTLA4, RabMAb CTLA4, CTLA-4, CD152, Insulin-Dependent Diabetes Mellitus 12, Cytotoxic T-Lymphocyte Protein 4, Celiac Disease 3, GSE, CD, Ligand And Transmembrane Spliced, Cytotoxic T Lymphocyte Associated Antigen 4, Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form, Cytotoxic T-Lymphocyte-Associated Serine Esterase-4, Cytotoxic T-Lymphocyte-Associated Antigen 4, CD152 Isoform, CD152 Antigen, CELIAC3, IDDM12, ALPS5, GRD4,CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation - a phenomenon which is particularly notable in cancers. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. CTLA4 is a member of the immunoglobulin superfamily. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 Molecules. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis. This antibody is made from a humanized Fab fragment of anti-CTLA4, ipilimumab or Yervoy, the first FDA approved immune checkpoint blockade therapy for cancer treatment. Humanized Recombinant Anti-CTLA4 fragment Antibody is useful for researchers interested in cancer research, immunodeficiency, and autoimmune diseases.

Gene ID: 1493

NCBI Accession: NP_001032720

UniProt: P16410

Pathways: Cancer Immune Checkpoints